Gene Expression Profiling of Breast Cancer

Ting Bao, Nancy E. Davidson

Research output: Contribution to journalArticle

Abstract

Gene expression profiling is enabling scientists to understand the heterogeneous nature of breast cancer on a genomic level. Several gene expression profiles for breast cancers have emerged in the initial studies and appear to be generally concordant in their ability to predict poor outcome. Of these profiles, the Oncotype Dx and Mammaprint assays are the best validated and are commercially available. Their role in clinical practice is being refined through ongoing clinical trials. Other efforts are directed at determining host factors that might help identify prognosis as well as response and toxicity of therapy. It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient.

Original languageEnglish (US)
Pages (from-to)249-260
Number of pages12
JournalAdvances in Surgery
Volume42
Issue numberC
DOIs
StatePublished - Sep 2008

Fingerprint

Gene Expression Profiling
Breast Neoplasms
Transcriptome
Patient Care
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Gene Expression Profiling of Breast Cancer. / Bao, Ting; Davidson, Nancy E.

In: Advances in Surgery, Vol. 42, No. C, 09.2008, p. 249-260.

Research output: Contribution to journalArticle

Bao, Ting ; Davidson, Nancy E. / Gene Expression Profiling of Breast Cancer. In: Advances in Surgery. 2008 ; Vol. 42, No. C. pp. 249-260.
@article{4b3e3c2159c247ce94483d9da793d327,
title = "Gene Expression Profiling of Breast Cancer",
abstract = "Gene expression profiling is enabling scientists to understand the heterogeneous nature of breast cancer on a genomic level. Several gene expression profiles for breast cancers have emerged in the initial studies and appear to be generally concordant in their ability to predict poor outcome. Of these profiles, the Oncotype Dx and Mammaprint assays are the best validated and are commercially available. Their role in clinical practice is being refined through ongoing clinical trials. Other efforts are directed at determining host factors that might help identify prognosis as well as response and toxicity of therapy. It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient.",
author = "Ting Bao and Davidson, {Nancy E.}",
year = "2008",
month = "9",
doi = "10.1016/j.yasu.2008.03.002",
language = "English (US)",
volume = "42",
pages = "249--260",
journal = "Advances in Surgery",
issn = "0065-3411",
publisher = "Academic Press Inc.",
number = "C",

}

TY - JOUR

T1 - Gene Expression Profiling of Breast Cancer

AU - Bao, Ting

AU - Davidson, Nancy E.

PY - 2008/9

Y1 - 2008/9

N2 - Gene expression profiling is enabling scientists to understand the heterogeneous nature of breast cancer on a genomic level. Several gene expression profiles for breast cancers have emerged in the initial studies and appear to be generally concordant in their ability to predict poor outcome. Of these profiles, the Oncotype Dx and Mammaprint assays are the best validated and are commercially available. Their role in clinical practice is being refined through ongoing clinical trials. Other efforts are directed at determining host factors that might help identify prognosis as well as response and toxicity of therapy. It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient.

AB - Gene expression profiling is enabling scientists to understand the heterogeneous nature of breast cancer on a genomic level. Several gene expression profiles for breast cancers have emerged in the initial studies and appear to be generally concordant in their ability to predict poor outcome. Of these profiles, the Oncotype Dx and Mammaprint assays are the best validated and are commercially available. Their role in clinical practice is being refined through ongoing clinical trials. Other efforts are directed at determining host factors that might help identify prognosis as well as response and toxicity of therapy. It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient.

UR - http://www.scopus.com/inward/record.url?scp=49849105624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849105624&partnerID=8YFLogxK

U2 - 10.1016/j.yasu.2008.03.002

DO - 10.1016/j.yasu.2008.03.002

M3 - Article

VL - 42

SP - 249

EP - 260

JO - Advances in Surgery

JF - Advances in Surgery

SN - 0065-3411

IS - C

ER -